✦ LIBER ✦

36 Gemcitabine has equivalent activity and lower toxicity compared with cisplatin + etoposide in advanced non-small cell lung cancer (NSCLC)

✍ Scribed by Perng, R.-P.; Chen, Y.-M.; Liu, J.-M.; Tsai, C.-M.; Whang-Peng, J.; Cho, H.-L.; Chang, S.; Nguyen, B.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Decreased myelotoxicity of gemcitabine a

✍ Cortesi, E.; Ramponi, S.; Corona, M.; Moscetti, L.; Grifalchi, F.; Oliva, A.; Le 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 73 KB

A prospective, multicentre clinical tria

✍ Tuncay GOKSEL; Osman Nuri HATIPOGLU; Can OZTURK; Metin GORGUNER; Murat KIYIK; Ug 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

185 Comparative evaluation of gemcitabin

✍ Roshan, V.; Jagadesan, P. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 44 KB

159 Phase II trial of gemcitabine in com

✍ Mohedano, N.; Sanchez-Rovira, P.; Medina, B.; Flores-Gonzalez, E.; Moreno, M.A.; 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 158 KB

Commentary on “Interim Analysis of a Pha

✍ Gregory A. Masters 📂 Article 📅 2000 🏛 CIG Media Group, LP. 🌐 English ⚖ 350 KB

Phase II trial with weekly cisplatin (CD

✍ Lopez, R.; Fernandez, R.; Virizuela, J.A.; Cueva, J.; Garcia, E.; Sanz, A.; Vale 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 157 KB